SCHEMBL3010751

SCHEMBL3010751

O=S(=O)(c1cccc(Br)c1)C1CCN(c2nc(-c3ccc(Cl)cc3)cs2)CC1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.50
MAPT P10636 8/20 0.50
NPC1 O15118 6/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
SMN1; SMN2 Q16637 8/20 0.49
MAPK1 P28482 4/20 0.49
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
LMNA P02545 4/20 0.45
HPGD P15428 1/20 0.45
FFAR2 O15552 1/20 0.44
TSHR P16473 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ALDH1A1 P00352 1/20 0.43
HTT P42858 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3022246 0.93 RAB9A (0.51) RAB9AMAPTNPC1CYP1A2CYP2C9
SCHEMBL3012682 0.91 MEN1 (0.52) RAB9AMAPTNPC1CYP1A2CYP2C9
SCHEMBL3015722 0.91 SMN1; SMN2 (0.55) RAB9AMAPTNPC1CYP1A2CYP2C9
SCHEMBL3007275 0.90 AR (0.53) RAB9AMAPTNPC1CYP1A2CYP2C9
SCHEMBL3018530 0.90 SMN1; SMN2 (0.53) RAB9AMAPTNPC1CYP1A2CYP2C9
SCHEMBL3000308 0.90 SMN1; SMN2 (0.52) RAB9AMAPTNPC1CYP1A2CYP2C9
SCHEMBL3016185 0.90 RAB9A (0.49) RAB9AMAPTNPC1CYP1A2CYP2C9
SCHEMBL3016769 0.90 SMN1; SMN2 (0.46) RAB9AMAPTNPC1CYP1A2CYP2C9
SCHEMBL3023016 0.89 SMN1; SMN2 (0.56) RAB9AMAPTNPC1SMN1; SMN2MAPK1
SCHEMBL3011415 0.89 SMN1; SMN2 (0.47) RAB9AMAPTNPC1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885MAPT 18/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.